Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. News
  7. Summary
    LUN   DK0061804697

LUNDBECK

(LUN)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-09-29 am EDT
22.49 DKK   -3.89%
09/13Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
CI
08/17Transcript : H. Lundbeck A/S, Q2 2022 Earnings Call, Aug 17, 2022
CI
08/17Lundbeck's sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the first half of 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

06/16/2022 | 03:00am EDT

H. Lundbeck A/S announced that the results from the DELIVER study have been recognized for their importance for the scientific and medical community. The results from the clinical study with Vyepti (eptinezumab) were accepted for publication in the prestigious journal Lancet Neurology, one of the most cited medical journals within neurology. The DELIVER study results were published online on June 15.

The DELIVER study investigated the efficacy and safety of Vyepti 100 mg and 300 mg IV infusion in patients with chronic or episodic migraine who had experienced 2-4 previous preventive treatment failures due to lack of efficacy or intolerable side effects. The DELIVER study met its primary objective of demonstrating statistically significant superiority of Vyepti versus placebo in reducing the number of monthly migraine days (MMDs) over 12 weeks of treatment and it also achieved statistical significance on all key secondary outcome measures. While 42% to 49% of patients who received Vyepti in the DELIVER study achieved a =50% reduction in MMDs over 12 weeks, other studies with subcutaneously administered monoclonal antibodies targeting CGRP or its receptor (erenumab, fremanezumab, and galcanezumab) in patients with migraine and 2-4 previous preventive treatment failures migraine report that 30-38% of patients achieved a =50% reduction in MMDs.

In addition to the reduction in frequency of migraine days for patients treated with Vyepti, a larger reduction in the percentage of severe attacks for the remaining headache episodes compared to placebo was observed.


ę S&P Capital IQ 2022
All news about LUNDBECK
09/13Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazo..
CI
08/17Transcript : H. Lundbeck A/S, Q2 2022 Earnings Call, Aug 17, 2022
CI
08/17Lundbeck's sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the..
AQ
08/17H. Lundbeck A/S Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
08/17H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022
CI
08/09Lundbeck raises financial guidance range for the full year 2022
AQ
08/09H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022
CI
07/26Lundbeck : Conducting largest study ever to observe early-stage multiple system atrophy
PU
07/13Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S made b..
AQ
07/12Transactions with shares and linked securities in H. Lundbeck A/S made by executives an..
AQ
More news
Financials
Sales 2022 17 696 M 2 325 M 2 325 M
Net income 2022 1 616 M 212 M 212 M
Net Debt 2022 2 340 M 308 M 308 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 24 092 M 3 166 M 3 166 M
EV / Sales 2022 1,49x
EV / Sales 2023 1,20x
Nbr of Employees 5 437
Free-Float 99,9%
Chart LUNDBECK
Duration : Period :
Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 23,40 DKK
Average target price 190,00 DKK
Spread / Average Target 712%
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
J÷rg Hornstein Chief Financial Officer
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LUNDBECK-30.71%3 227
JOHNSON & JOHNSON-2.75%437 390
ELI LILLY AND COMPANY12.63%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
PFIZER, INC.-24.76%249 357